Kosan Announces Third Quarter 2007 Financi...(President and Chief Executive Officer. ...)

Date:11/8/2007

President and Chief Executive Officer. "We believe that the growing body of positive clinical data that we have generated in our clinical trials to date, combined with development and regulatory strategies that are being successfully implemented in all of our clinical programs and the commercial potential of our Hsp90 and epothilone programs, position Kosan as an attractive investment opportunity."

Third Quarter 2007 Highlights

-- Kosan reached a binding agreement with the U.S. Food and Drug

Administration (FDA) on the design of Kosan's TIME-1 clinical trial, a

pivotal Phase 3 trial of Kosan's Hsp90 inhibitor tanespimycin as a

treatment for patients with multiple myeloma, through a Special

Protocol Assessment (SPA) process with the FDA. Kosan also completed

the "Scientific Advice" process with the centralized European Medicines

Agency (EMEA) for TIME-1.

-- At the 2007 Breast Cancer Symposium of the American Society of Clinical

Oncology (ASCO), Kosan presented updated data from a Phase 1 clinical

trial showing that Kosan's Hsp90 inhibitor alvespimycin demonstrated

antitumor activity and tolerability in combination with trastuzumab

(Herceptin(R)), with clinical benefit observed in 42% of evaluable

patients (8 of 19 evaluable) with HER2-positive metastatic breast

cancer.

-- Pfizer Inc. initiated a Phase 1 clinical trial designed to test the

safety, tolerability and pharmacokinetics of motilin receptor agonist

KOS-2187, a selective and potent motilin receptor agonist being

developed for the treatment of gastroesophageal reflux disease (GERD)

and potentially other gastrointestinal disorders.

-- Kosan completed preparations and is planning to initiate later this

quarter a Phase 2 clinical trial of alvespimycin in patients with

newly-diagnosed HER2-positive metastatic breast cance
'/>"/>

SOURCE Kosan Biosciences Incorporated Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related biology technology :

1. Kosan Biosciences to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Kosan Biosciences to Present at the 2007 UBS Global Life Sciences Conference
3. Kosan Biosciences to Present at the Biotechnology Industry Organization Investor Forum
4. Kosan Biosciences to Host Research & Development Day on October 31, 2007
5. Kosan to Reacquire Epothilone Program From Roche
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results